AIM ImmunoTech Files Preliminary Prospectus for Rights Offering

MT Newswires Live01-24 02:44

AIM ImmunoTech (AIM) on Friday filed a preliminary prospectus with the US Securities and Exchange Commission for a rights offering.

The offering may raise as much as $12 million, the company said.

Each subscription right entitles holders to purchase one unit for every share of the company's common stock they own. Each unit, priced at $1,000, consists of one share of Series G convertible preferred stock and 1,492 warrants to purchase common stock, the company said.

The offering covers up to 12,000 units, representing up to 12,000 preferred shares and 17.9 million warrants. In total, the securities may result in as many as 26.9 million common shares being issued upon conversion of the preferred stock and exercise of the warrants.

The preferred shares convert at an initial price of $1.34 per share, and the warrants are exercisable at the same price for five years.

The subscription rights are non-transferable and will be distributed to shareholders of record as of Feb. 4.

Net proceeds from any sale would be used for general corporate purposes.

AIM shares fell 4.8% in Friday trading.

Price: 1.20, Change: -0.06, Percent Change: -4.76

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605240774?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-24 02:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605240774","market":"hk","top_or_hot":-1,"title":"AIM ImmunoTech Files Preliminary Prospectus for Rights Offering","media":"MT Newswires Live","content":"<html><body><p> AIM ImmunoTech (AIM) on Friday filed a preliminary prospectus with the US Securities and Exchange Commission for a rights offering.</p><p>The offering may raise as much as $12 million, the company said.</p><p>Each subscription right entitles holders to purchase one unit for every share of the company's common stock they own. Each unit, priced at $1,000, consists of one share of Series G convertible preferred stock and 1,492 warrants to purchase common stock, the company said.</p><p>The offering covers up to 12,000 units, representing up to 12,000 preferred shares and 17.9 million warrants. In total, the securities may result in as many as 26.9 million common shares being issued upon conversion of the preferred stock and exercise of the warrants.</p><p>The preferred shares convert at an initial price of $1.34 per share, and the warrants are exercisable at the same price for five years.</p><p>The subscription rights are non-transferable and will be distributed to shareholders of record as of Feb. 4.</p><p>Net proceeds from any sale would be used for general corporate purposes.</p><p>AIM shares fell 4.8% in Friday trading.</p><p>Price: 1.20, Change: -0.06, Percent Change: -4.76</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIM ImmunoTech Files Preliminary Prospectus for Rights Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIM ImmunoTech Files Preliminary Prospectus for Rights Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-24 02:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AIM ImmunoTech (AIM) on Friday filed a preliminary prospectus with the US Securities and Exchange Commission for a rights offering.</p><p>The offering may raise as much as $12 million, the company said.</p><p>Each subscription right entitles holders to purchase one unit for every share of the company's common stock they own. Each unit, priced at $1,000, consists of one share of Series G convertible preferred stock and 1,492 warrants to purchase common stock, the company said.</p><p>The offering covers up to 12,000 units, representing up to 12,000 preferred shares and 17.9 million warrants. In total, the securities may result in as many as 26.9 million common shares being issued upon conversion of the preferred stock and exercise of the warrants.</p><p>The preferred shares convert at an initial price of $1.34 per share, and the warrants are exercisable at the same price for five years.</p><p>The subscription rights are non-transferable and will be distributed to shareholders of record as of Feb. 4.</p><p>Net proceeds from any sale would be used for general corporate purposes.</p><p>AIM shares fell 4.8% in Friday trading.</p><p>Price: 1.20, Change: -0.06, Percent Change: -4.76</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIM.AU","symbol_name":"Ai-Media Technologies Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2605240774","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605240774","pubTimestamp":1769193890,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AIM ImmunoTech  on Friday filed a preliminary prospectus with the US Securities and Exchange Commission for a rights offering.The offering may raise as much as $12 million, the company said.Each subscription right entitles holders to purchase one unit for every share of the company's common stock they own. Each unit, priced at $1,000, consists of one share of Series G convertible preferred stock and 1,492 warrants to purchase common stock, the company said.The offering covers up to 12,000 units, representing up to 12,000 preferred shares and 17.9 million warrants. In total, the securities may result in as many as 26.9 million common shares being issued upon conversion of the preferred stock and exercise of the warrants.The preferred shares convert at an initial price of $1.34 per share, and the warrants are exercisable at the same price for five years.The subscription rights are non-transferable and will be distributed to shareholders of record as of Feb. 4.Net proceeds from any sale w","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIM.AU":"Ai-Media Technologies Ltd","BK7064":"综合支持服务","BK4139":"生物科技","BK4557":"大麻股","AIM":"AIM ImmunoTech Inc."},"translate_title":"AIM ImmunoTech提交供股初步招股说明书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM.AU":1,"AIM":1.5},"content_text":"AIM ImmunoTech (AIM) on Friday filed a preliminary prospectus with the US Securities and Exchange Commission for a rights offering.The offering may raise as much as $12 million, the company said.Each subscription right entitles holders to purchase one unit for every share of the company's common stock they own. Each unit, priced at $1,000, consists of one share of Series G convertible preferred stock and 1,492 warrants to purchase common stock, the company said.The offering covers up to 12,000 units, representing up to 12,000 preferred shares and 17.9 million warrants. In total, the securities may result in as many as 26.9 million common shares being issued upon conversion of the preferred stock and exercise of the warrants.The preferred shares convert at an initial price of $1.34 per share, and the warrants are exercisable at the same price for five years.The subscription rights are non-transferable and will be distributed to shareholders of record as of Feb. 4.Net proceeds from any sale would be used for general corporate purposes.AIM shares fell 4.8% in Friday trading.Price: 1.20, Change: -0.06, Percent Change: -4.76","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605240774","isCrawlerRequest":true}